Supriya Lifescience Share Price | Supriya Lifescience Stock Screener
SUPRIYA
Pharmaceuticals
Share Price NSE
₹840.50
▲
7.60 (0.91%)
Share Price BSE
₹840.15
▲
7.60 (0.91%)
As of July 24, 2026, the Supriya Lifescience share price (NSE: SUPRIYA) is ₹840.50 on NSE and ₹840.15 on BSE, up 0.91% from the previous close, with shares trading between ₹820.00 and ₹846.00, and a 52-week range of ₹553.35–₹1,052.50.
Analyse Supriya Lifescience share price performance and track historical price performance.
Use the Supriya Lifescience stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Supriya Lifescience Market Cap
₹6,950.49 Cr.
SUPRIYA P/E Ratio (TTM)
32.21
Supriya Lifescience P/B Ratio
5.62
EPS (TTM)
₹25.98
Dividend Yield
0.12%
Debt to Equity
0.01
SUPRIYA 52 Week High
₹1052.50
Supriya Lifescience 52 Week Low
₹553.35
Operating Margin
35.00%
Profit Margin
25.72%
SUPRIYA Revenue (TTM)
₹828.00
EBITDA
₹294.00
Net Income
₹213.00
Total Assets
₹1,357.00
Total Equity
₹1,198.00
Supriya Lifescience Share Price Chart
Screen Supriya Lifescience share price with an interactive chart. Analyse SUPRIYA price trends and volatility across different timeframes.
Supriya Lifescience Company Profile - Fundamental Screener
Screen Supriya Lifescience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SUPRIYA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE07RO01027
Supriya Lifescience Balance Sheet Screener
Screen SUPRIYA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,357 | 1,112 | 921 | 820 | 735 | 446 | 336 | 253 | 245 | 241 |
| Current Assets | 532 | 437 | 398 | 465 | 498 | 266 | 196 | 133 | 120 | 115 |
| Fixed Assets | 725 | 453 | 310 | 262 | 190 | 100 | 99 | 85 | 91 | 89 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 38 | 33 | 29 | 25 | 19 | 31 | 32 | 24 | 45 | 51 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,198 | 997 | 815 | 700 | 616 | 269 | 149 | 94 | 55 | 46 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 15 | 15 | 15 | 15 | 15 |
| Reserves & Surplus | 1,182 | 981 | 799 | 683 | 600 | 254 | 134 | 79 | 40 | 31 |
Supriya Lifescience Income Statement Screener - Profit & Revenue Analysis
Screen Supriya Lifescience income statement and profit fundamentals.
Analyze SUPRIYA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Supriya Lifescience share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 828 | 706 | 581 | 470 | 538 | 396 | 323 | 286 | 222 | 191 | 172 | 140 |
| Expenses | 534 | 436 | 397 | 332 | 316 | 218 | 213 | 213 | 191 | 166 | 150 | 121 |
| EBITDA | 294 | 271 | 184 | 138 | 222 | 178 | 110 | 73 | 31 | 25 | 22 | 20 |
| Operating Profit % | 35.00% | 37.00% | 30.00% | 28.00% | 40.00% | 44.00% | 32.00% | 23.00% | 10.00% | 9.00% | 12.00% | 12.00% |
| Depreciation | 28 | 20 | 16 | 12 | 10 | 7 | 6 | 5 | 5 | 5 | 4 | 3 |
| Interest | 2 | 2 | 2 | 3 | 4 | 4 | 7 | 10 | 11 | 12 | 10 | 7 |
| Profit Before Tax | 275 | 249 | 166 | 124 | 207 | 167 | 96 | 57 | 15 | 8 | 8 | 10 |
| Tax | 61 | 61 | 47 | 34 | 55 | 44 | 23 | 18 | 6 | 2 | 2 | 2 |
| Net Profit | 213 | 188 | 119 | 90 | 152 | 124 | 73 | 39 | 9 | 6 | 6 | 8 |
| EPS | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 10.02 | 5.39 | 1.19 | 3.87 | 3.89 | 16.82 |
Supriya Lifescience Cash Flow Screener - Liquidity Fundamentals
Screen SUPRIYA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 165 | 113 | 64 | 49 | 76 | 117 | 49 | 28 | 27 | 14 |
| Investing Activities | -152 | -174 | -124 | -60 | -47 | -25 | 5 | -5 | -27 | -33 |
| Financing Activities | -8 | -22 | -10 | 150 | -15 | -29 | -50 | -20 | -2 | 21 |
| Net Cash Flow | 4 | -83 | -70 | 139 | 15 | 62 | 4 | 3 | -2 | 2 |
Supriya Lifescience Shareholding Pattern Screener
See Supriya Lifescience shareholding pattern with promoter, FII, and DII holdings.
Check Supriya Lifescience promoter holding and ownership changes for SUPRIYA on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| FII Holding | 5.16% | 7.19% | 6.78% | 5.46% | 5.20% | 5.36% | 4.95% | 6.03% |
| DII Holding | 5.70% | 4.26% | 4.86% | 5.22% | 5.01% | 5.30% | 5.48% | 5.45% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.22% | 16.40% | 16.39% | 16.77% | 16.66% | 17.06% | 17.19% | 0.00% |
| Other Holding | 4.63% | 3.85% | 3.67% | 4.25% | 4.83% | 3.98% | 4.08% | 20.23% |
| Shareholder Count | 81,161 | 91,051 | 91,928 | 87,912 | 85,099 | 87,980 | 89,621 | 85,328 |
Supriya Lifescience Share Dividend Screener - Share Yield Analysis
Check Supriya Lifescience dividend history with payout and yield data.
View Supriya Lifescience dividend details including ex-dates and amounts for SUPRIYA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.18% |
| 2024-March | ₹0.80 | 0.11% |
| 2023-March | ₹0.60 | 0.18% |
| 2022-March | ₹0.60 | 0.32% |
| 2021-March | ₹0.54 | 0.11% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Supriya Lifescience Stock Index Membership
See which indices include Supriya Lifescience stock.
Check SUPRIYA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Supriya Lifescience Market Events Screener - Corporate Actions
Get Supriya Lifescience corporate actions including splits, bonuses, and buybacks.
Check Supriya Lifescience stock events that may affect SUPRIYA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 8.24% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 0.36% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -6.66% |
| 2025-09-24 | 2025-09-24 | Annual General Meeting | NA | 11.37% |
| 2025-09-04 | 2025-09-05 | Dividend | ₹ 1.00 /share | -11.70% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -0.96% |
| 2025-05-27 | 2025-05-27 | Quarterly Result Announcement | NA | 5.82% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 9.11% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -1.41% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -6.20% |
| 2024-09-20 | 2024-09-21 | Dividend | ₹ 0.80 /share | 74.84% |
| 2023-09-15 | 2023-09-15 | Dividend | ₹ 0.60 /share | 13.53% |
| 2022-09-01 | 2022-09-02 | Dividend | ₹ 0.60 /share | -0.06% |
Supriya Lifescience Competitors Screener - Peer Comparison
Screen SUPRIYA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 470,726 | 40.78 | 61,674 | 12.69% | 11,565 | 68.02 |
| Divis Laboratories | 194,588 | 75.69 | 11,067 | 13.95% | 2,568 | 71.98 |
| Torrent Pharmaceuticals | 191,732 | 79.19 | 13,886 | 20.34% | 2,138 | 66.68 |
| Cipla | 115,724 | 30.16 | 29,045 | 2.24% | 3,870 | 52.50 |
| Zydus Life Science | 115,023 | 22.33 | 27,658 | 17.64% | 5,026 | 58.19 |
| Lupin | 114,985 | 21.16 | 29,039 | 26.75% | 5,356 | 63.60 |
| Mankind Pharma | 106,532 | 54.68 | 14,636 | 14.85% | 1,938 | 60.75 |
| Dr Reddys Laboratories | 100,661 | 24.56 | 35,059 | 3.90% | 4,158 | 32.84 |
| Aurobindo Pharma | 90,892 | 25.88 | 33,385 | 3.21% | 3,376 | 58.93 |
| Laurus Labs | 86,010 | 94.61 | 6,868 | 22.01% | 890 | 67.71 |
Supriya Lifescience Company Announcements - News Screener
Screen SUPRIYA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - | |
| 2026-07-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-04 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015. | - |
| 2026-06-23 | Email Communication To Shareholders Regarding Dividend Taxation Provisions. | - |
| 2026-06-20 | Closure of Trading Window | - |
| 2026-06-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-02 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-27 | Corporate Action-Board to consider Dividend | - |
| 2026-05-27 | Audited Financial Results For Quarter And Year Ended March 31 2026 | - |
| 2026-05-27 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-20 | Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended March 31 2026 And Recommend Dividend If Any On The Equity Shares Of The Company For The Financial Year Ended March 31 2026. | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-22 | Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 - Update On Inspection By United States Food & Drug Administration (USFDA) | - |